
The research proposal describes a project aimed at synthesizing and testing small molecule inhibitors of the secretion of proprotein convertase subtilisin/kexin type 9 (PCSK9). Such molecules hold great potential for the treatment of hyperlipidemia in human patients.
The WARF Accelerator Program speeds commercialization of UW–Madison discoveries that have been patented by WARF by providing targeted funding and expert advice from seasoned business mentors known as Catalysts. WARF Accelerator support helps inventions achieve technical milestones and advance to the marketplace.